Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

AVEO CLASS ACTION ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors of Important April 26th Deadline in Securities Class Action Lawsuit; Encourages Investors With Losses in Excess of $100K to Contact the Firm – AVEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/15/2019 | 05:47pm EDT

NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive (the “Class Period”) of the important April 26, 2019 lead plaintiff deadline in the securities class action lawsuit filed against the company. The lawsuit seeks to recover damages for AVEO investors under the federal securities laws.

To join the AVEO class action, go to https://www.rosenlegal.com/cases-register-1519.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the TIVO-3 trial was inadequately designed to address the overall survival concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented back in the June 2013; (2) tivozanib had insufficient survival data to obtain U.S. Food and Drug Administration (“FDA”) approval following its initial rejection by the FDA in 2013; (3) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (4) as a result, AVEO’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 26, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://www.rosenlegal.com/cases-register-1519.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.

-------------------------------

Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY  10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Companies"
04:35aRYMAN HOSPITALITY PROPERTIES : and Gray Television Announce Joint Venture to Create Premium Content Service for Country Lifestyle Consumers
AQ
04:35aGLOBAL PAYMENTS : NMI Expands Executive Team to Support Next Growth Phase
AQ
04:35aNITESH ESTATES : Ropes in New CEO and CFO
AQ
04:35aRELIANCE INS : Softbank investing in Jio as Mukesh Ambani deleverages business
AQ
04:35aQANTAS AIRWAYS : ' Airbus A380, and first class, returns to Sydney-Hong Kong
AQ
04:35aKRAFT HEINZ : Appoints New CEO With An Eye On Organic Growth
AQ
04:35aUNITED HEALTH PRODUCTS : Retains IQVIA to Conduct U.S. Market Commercialization Study of HemoStyp in Support of Socit Gnrales Strategic Review
AQ
04:35aHABIB BANK : NAB apprehended fake accounts accused
AQ
04:35aPSX gain 100 point to close at 36,504 points
AQ
04:35aP I A C A : Committee discusses amendments in rules of Senate
AQ
Latest news "Companies"
Advertisement